In the COMET-1 trial, 682 patients with castrate-resistant prostate cancer who progressed after docetaxel and androgen modulators (abiraterone and/or enzalutamide) were randomly assigned to either cabozantinib (MET inhibitor) or prednisone. This evidence concerns the gene MET and Familial prostate cancer.